<DOC>
	<DOCNO>NCT02046850</DOCNO>
	<brief_summary>Study assess effect Rifampicin pharmacokinetics Selumetinib ( AZD6244 ; ARRY-142886 ) ( Hyd-Sulfate ) Healthy Male Volunteers</brief_summary>
	<brief_title>To Assess Effect Rifampicin Pharmacokinetics Selumetinib Healthy Male Volunteers</brief_title>
	<detailed_description>A Open-label , Single-center Study Assess Effect CYP3A4 inducer Rifampicin Pharmacokinetics 75 mg Single Oral Dose Selumetinib ( AZD6244 ; ARRY-142886 ) ( Hyd-Sulfate ) Healthy Volunteers</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<criteria>1 . Have body mass index ( BMI ) 18 30 kg/m2 ( inclusive ) weigh least 50 kg 100 kg ( inclusive ) . 2 . Must smoke use nicotine product within previous 3 month . 3 . Have calculate creatinine clearance ( CrCL ) great 50 mL/min use CockcroftGault formula . 1 . Subjects Japanese nonJapanese Asian ethnicity . 2 . Any one parent grandparent ( maternal paternal ) Japanese nonJapanese Asian ( eg , China , Taiwan , Korea , Philippines , Thailand , Vietnam Malaysia ) . Asian Indians acceptable . 3 . Current past history central serous retinopathy retinal vein thrombosis , intraocular pressure great 21 mmHg uncontrolled glaucoma . 4 . Any clinically relevant abnormal finding physical examination , hematology , clinical chemistry , urinalysis , vital sign ECG baseline opinion investigator . 5 . History presence clinically significant disease disorder opinion investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Phase I , healthy , pharmacokinetics ,</keyword>
</DOC>